Dr. Burn is a successful senior scientist, leader and business executive with a lifelong mission, focus and passion of improving the human condition by delivering products, cures and care to patients and their families. As a senior executive with extensive global industry and international management experience, he has a proven track record of success in Academia, Pharmaceutical R&D, Biotech, Not-for-Profit and Integrated Health Care organizations. He designed, implemented and led multiple patient-centric programs which resulted in successful basic and translational research and development programs, in the pharmaceutical, nutrition, diagnostic, personalized medicine, treatment and cure areas. With over 30 years of experience in pharmaceutical and nutritional R&D and academia, he spearheaded many programs, from the gene to the clinics and through marketed products in the Endocrine, Metabolic Diseases, Cardiovascular, Renal, Bone, Musculoskeletal, Autoimmunity, Inflammation, Neuroscience, Dermatology, Oncology and Women’s Health therapeutic areas. Under his leadership multiple programs resulted in the successful identification of clinical candidate molecules, their evaluation in humans and subsequent market introduction.

Most recently he served as Professor of Pediatrics at the Sanford School of Medicine and as Scientific Founder, CEO and President of Metabolic Health & Fitness. In addition, he was the acting Chair and Director of The Sanford Project at Sanford Health, the largest rural health care provider in the US. He also serves on several company Boards and Scientific Advisory Boards of Universities, Biotech companies and Government agencies.

Dr. Burn gained extensive international leadership and R&D experience in the Pharmaceutical and Biotech industry, in Academia, Not-for-Profit and Health Care organizations. He served in the position of Senior Vice President of Research & Development at the Juvenile Diabetes Research Foundation (JDRF); at Hoffman-La Roche as the Global Head for the Metabolic Diseases Therapeutic Area and as Vice President of Biotechnology; at Eli Lilly & Company where he performed as the Vice President of Endocrine Research & Clinical Investigation; as Vice President of Research & Development for the Nutrition division at Monsanto/Pharmacia; and as Vice President of Metabolic Disease Research & Development at Bayer Health Care.

Previously, he held positions at various academic institutions, including the University of California, San Diego, CA and the University of Basel, Switzerland. He authored more than a hundred articles in some of the most prestigious scientific journals.

Metabolic Diseases; Endocrinology; Metabolic Disorders; Metabolic Control; Metabolic Fitness; Cardiovascular Diseases; Renal Diseases; Bone Diseasesl Musculoskeletal Diseases; Inflammatory Diseases; Autoimmune Diseases; β-Cell Biology; β-Cell Regeneration; Type 1 Diabetes; Type 2 Diabetes; Obesity; Drug Discovery; Development; Translational Research; Clinical Research; Clinical Development; Clinical Trials; Translational Medicine Personalized Medicine; Nutrition.